Bulk Pharmaceutical API Sources for prednisolone tebutate

Bulk Pharmaceutical API Sources for prednisolone tebutate

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-006-118-951
BOC Sciences		7681-14-3
MedChemexpress MCE		HY-U00098
AbaChemScene		CS-7134
OChem		15424

Prednisolone Tebutate API Sourcing Landscape

Last updated: February 19, 2026

This analysis identifies key global suppliers of bulk prednisolone tebutate active pharmaceutical ingredient (API), detailing manufacturing capabilities, regulatory compliance, and market presence. The landscape is characterized by a concentration of manufacturers in India and China, with a growing emphasis on meeting stringent international quality standards.

Who are the Primary Global Manufacturers of Prednisolone Tebutate API?

The global supply of prednisolone tebutate API is primarily driven by manufacturers in Asia, with India and China representing the largest production hubs. Several companies have established significant manufacturing capacities and possess the necessary regulatory approvals to serve international markets.

Key Manufacturers and Their Capabilities:

• Laurus Labs (India):
  • Established presence in steroid API manufacturing.
  • cGMP compliant facilities.
  • Supplies to regulated markets including the US and Europe.
  • Reported to have significant capacity for corticosteroids.
• Divi's Laboratories (India):
  • One of the largest API manufacturers globally.
  • cGMP, USFDA, EDQM certified facilities.
  • Has a broad portfolio of APIs, including steroids.
  • Strong export focus, serving major pharmaceutical companies.
• Abbott India Limited (India):
  • While primarily known for finished formulations, Abbott has API manufacturing capabilities or strong sourcing partnerships.
  • Adheres to global quality standards.
• Zydus Lifesciences (formerly Cadila Healthcare) (India):
  • Vertically integrated operations, including API manufacturing.
  • cGMP compliant, with approvals from various regulatory bodies.
  • Active in the corticosteroid segment.
• Jiangsu Hengrui Medicine Co., Ltd. (China):
  • Significant player in the Chinese pharmaceutical market with API production.
  • Focus on R&D and large-scale manufacturing.
  • Exporting APIs to various international markets.
• Sichuan Kelun Pharmaceutical Co., Ltd. (China):
  • Large Chinese pharmaceutical group with substantial API production.
  • Investments in advanced manufacturing technologies.
  • Compliance with international standards is a key focus for export markets.
• Lianyungang HEC Pharm. Co., Ltd. (China):
  • Specializes in corticosteroids and other steroids.
  • cGMP certified manufacturing facilities.
  • Export-oriented production, aiming for global regulatory compliance.

Table 1: Comparative Overview of Prednisolone Tebutate API Manufacturers

Manufacturer Name	Country	Primary Focus Areas	Regulatory Compliance (Examples)	Approximate Capacity (Metric Tons/Year)	Notes
Laurus Labs	India	Steroids, APIs for Antivirals, Oncology, Cardiovascular	USFDA, EDQM	Not Publicly Disclosed	Strong R&D and manufacturing infrastructure.
Divi's Laboratories	India	APIs, Custom Synthesis, Neutraceuticals	USFDA, EDQM, WHO	Not Publicly Disclosed	Largest API manufacturer by revenue from India.
Zydus Lifesciences	India	APIs, Finished Formulations	USFDA, EDQM, PMDA	Not Publicly Disclosed	Vertically integrated API to finished dosage form.
Jiangsu Hengrui Medicine	China	APIs, Oncology drugs	CFDA, USFDA (pending/target)	Not Publicly Disclosed	Significant investment in R&D and production scale.
Sichuan Kelun Pharmaceutical	China	APIs, Antibiotics, Cardiovascular drugs	CFDA, WHO	Not Publicly Disclosed	Expanding global reach for API exports.
Lianyungang HEC Pharm.	China	Steroids	CFDA, EDQM (target)	Not Publicly Disclosed	Specializes in corticosteroid production.

Capacity figures are estimates and not publicly disclosed by manufacturers. This table focuses on companies with reported capabilities in steroid APIs and potential for prednisolone tebutate production.

What Regulatory Standards Must API Manufacturers Adhere To?

Manufacturers of prednisolone tebutate API must comply with a rigorous framework of international and national regulations to ensure product quality, safety, and efficacy. Key among these are Good Manufacturing Practices (GMP), which are enforced by regulatory agencies worldwide.

Core Regulatory Requirements:

• Current Good Manufacturing Practices (cGMP):
  • Mandated by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national regulatory bodies.
  • Encompasses all aspects of production, including raw material sourcing, manufacturing processes, quality control, facility design, equipment validation, personnel training, and record-keeping.
  • Specific cGMP guidelines are outlined in various publications, such as the FDA's 21 CFR Parts 210 and 211, and the EMA's EudraLex Volume 4.
• International Conference on Harmonisation (ICH) Guidelines:
  • ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is the foundational guideline for API manufacturing.
  • Provides internationally accepted standards for quality management systems, personnel, buildings and facilities, process equipment, documentation and records, materials management, production and in-process controls, packaging and identification labeling of APIs, storage and distribution, and validation.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):
  • Manufacturers often file DMFs (in the US) or ASMFs (in Europe) with regulatory authorities.
  • These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API.
  • They are reviewed by regulatory agencies as part of the drug product approval process.
• Site Inspections and Audits:
  • Manufacturing facilities are subject to regular inspections by regulatory agencies (e.g., FDA, EMA, national health authorities) and audits by prospective customers.
  • Successful inspection outcomes are critical for market access.
• Pharmacopoeial Standards:
  • APIs must meet the specifications defined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These define acceptable limits for purity, impurities, assay, and other quality attributes.
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals):
  • For APIs exported to the European Union, compliance with REACH regulations is necessary, particularly concerning chemical safety and environmental impact.

Table 2: Key Regulatory Bodies and Their Role in API Oversight

Regulatory Body	Region/Country	Primary Function	Oversight Mechanism
FDA	United States	Regulates pharmaceuticals and medical devices	cGMP inspections, DMF review, Site registration
EMA	European Union	Evaluates medicinal products and supervises them for the EU	GMP inspections (via national agencies), ASMF review, QP certification
PMDA	Japan	Ensures safety, efficacy, and quality of pharmaceuticals	GMP inspections, DMF review
NMPA (formerly CFDA)	China	Regulates drugs and medical devices	GMP inspections, API registration
Health Canada	Canada	Regulates drugs and health products	GMP inspections, Drug Master File (DMF) submission
TGA	Australia	Regulates therapeutic goods	GMP inspections, ARTG listing
CDSCO	India	Regulates drugs and medical devices	GMP certification, inspection

Compliance with these standards is non-negotiable for any supplier aiming to serve the global pharmaceutical market with prednisolone tebutate API.

What are the Key Considerations for Sourcing Prednisolone Tebutate API?

Sourcing prednisolone tebutate API requires a multi-faceted approach, balancing cost, quality, reliability, and regulatory compliance. Pharmaceutical companies must conduct thorough due diligence on potential suppliers.

Critical Sourcing Factors:

1. Quality and Purity:
   • Impurity Profile: Prednisolone tebutate is a corticosteroid, and specific impurity limits are critical. Manufacturers must demonstrate robust control over process-related impurities and degradation products. Common impurities might include related steroids, residual solvents, and heavy metals.
   • Assay and Potency: The API must consistently meet specified potency requirements.
   • Physical Characteristics: Particle size distribution, crystal form (polymorphism), and bulk density can significantly impact downstream formulation processes (e.g., dissolution rates, processability). Manufacturers should provide detailed specifications.
2. Regulatory Compliance and Documentation:
   • DMF/ASMF Availability: A comprehensive and up-to-date DMF or ASMF is essential for drug product manufacturers seeking regulatory approval.
   • cGMP Certification: Facilities must be certified by relevant regulatory bodies (FDA, EMA, etc.) and pass customer audits.
   • Certificate of Analysis (CoA): Each batch must be accompanied by a detailed CoA confirming it meets all specified parameters.
   • Traceability: The ability to trace raw materials and manufacturing steps for each batch is crucial for quality assurance and recall management.
3. Manufacturing Capacity and Reliability:
   • Production Scale: The supplier must have sufficient capacity to meet current and projected demand. Fluctuations in supply can disrupt drug production schedules.
   • Lead Times: Predictable and manageable lead times for order fulfillment are necessary for inventory planning.
   • Business Continuity: The supplier's contingency plans for disruptions (e.g., natural disasters, geopolitical instability, equipment failure) should be assessed.
4. Cost-Effectiveness:
   • While quality and reliability are paramount, the API price is a significant factor in the overall cost of goods. Benchmarking prices across qualified suppliers is necessary.
   • Consider total cost of ownership, including freight, customs, and quality assurance costs.
5. Technical Support and Responsiveness:
   • Suppliers should offer strong technical support, including process insights and assistance with regulatory filings.
   • Prompt and effective communication regarding orders, shipments, and any quality-related issues is vital.
6. Geopolitical and Supply Chain Risks:
   • Diversification of suppliers across different geographic regions can mitigate risks associated with trade disputes, political instability, or localized production issues.
   • Understanding the raw material sourcing for the API itself is also important.

Table 3: Risk Assessment Matrix for API Sourcing

Risk Category	Potential Impact	Mitigation Strategies
Quality Failure	Batch rejection, product recalls, patient harm	Rigorous supplier qualification, in-house testing, comprehensive CoA review, regular audits
Supply Interruption	Production delays, stock-outs, market share loss	Dual sourcing, robust inventory management, supplier capacity assessment, business continuity planning
Regulatory Non-Compliance	Delayed approvals, market access denial	Verify cGMP status, review DMF/ASMF, pre-audit suppliers, ensure robust documentation
Price Volatility	Increased COGS, reduced profitability	Long-term contracts, competitive bidding, explore alternative suppliers
Intellectual Property (IP) Risk	Legal challenges, patent infringement	Ensure suppliers have clear IP rights for their manufacturing processes, review patent landscape
Geopolitical Instability	Supply chain disruption, tariffs, sanctions	Geographic diversification of suppliers, monitor global political climate, assess impact of trade policies

What is the Market Outlook for Prednisolone Tebutate API?

The market for prednisolone tebutate API is influenced by the demand for its finished pharmaceutical products, primarily in topical corticosteroids for dermatological applications. The market is characterized by established players and a focus on generics.

Market Dynamics:

• Growing Dermatological Market: The prevalence of skin conditions such as eczema, psoriasis, and allergic dermatitis drives demand for topical corticosteroids, including those formulated with prednisolone tebutate.
• Generic Competition: Prednisolone tebutate is an established molecule, and the market is largely driven by generic drug manufacturers. This creates pressure on API pricing.
• Emerging Markets: Increasing healthcare access and a rising middle class in emerging economies are contributing to the growth of the dermatology market and, consequently, API demand.
• Regulatory Scrutiny: Continued emphasis on quality and regulatory compliance by global health authorities means that manufacturers must maintain high standards. This can act as a barrier to entry for less established players.
• Innovations in Drug Delivery: While not directly impacting API manufacturing, advancements in topical drug delivery systems could indirectly influence the types of API characteristics (e.g., particle size, solubility) that formulators seek.

Market Challenges:

• Price Pressure: Intense competition among API manufacturers, particularly from India and China, leads to significant price pressure.
• Consolidation: The API manufacturing sector can experience consolidation, as larger players acquire smaller ones or merge to achieve economies of scale.
• Raw Material Sourcing: Fluctuations in the cost and availability of key steroid precursors can impact API pricing and supply.

Future Trends:

• Continuous Manufacturing: Adoption of continuous manufacturing processes by API producers could lead to improved efficiency, consistency, and reduced costs.
• Green Chemistry: Increasing focus on environmentally sustainable manufacturing practices may lead to the adoption of greener synthesis routes for corticosteroids.
• Enhanced Analytical Techniques: Advancements in analytical technologies will further enable stricter impurity profiling and quality control.

The market is expected to maintain a steady growth trajectory, driven by the persistent demand for dermatological treatments and the expansion of healthcare services globally. Suppliers who can consistently offer high-quality, compliant API at competitive prices will continue to dominate.

Key Takeaways

• The global prednisolone tebutate API supply is concentrated among manufacturers in India and China, with companies like Laurus Labs, Divi's Laboratories, Jiangsu Hengrui Medicine, and Sichuan Kelun Pharmaceutical being significant players.
• Adherence to stringent international regulatory standards, particularly cGMP and ICH guidelines, is paramount for API manufacturers seeking to supply regulated markets.
• Key sourcing considerations include API quality and purity, comprehensive regulatory documentation (DMF/ASMF), manufacturing capacity, reliability, cost-effectiveness, and technical support.
• The market outlook for prednisolone tebutate API is stable, driven by the ongoing demand for dermatological products, though it faces price pressures due to generic competition.

Frequently Asked Questions

1. What are the primary uses for prednisolone tebutate? Prednisolone tebutate is used in topical pharmaceutical formulations, primarily as an anti-inflammatory agent to treat various dermatological conditions like eczema, psoriasis, and dermatitis.

2. Are there any specific patent expiries related to prednisolone tebutate that impact API sourcing? Prednisolone tebutate itself is a well-established molecule with expired primary patents. The focus for API sourcing is on current Good Manufacturing Practices (cGMP) compliance and proprietary manufacturing process improvements rather than composition of matter patents for the API itself.

3. What is the typical lead time for procuring bulk prednisolone tebutate API from established manufacturers? Lead times can vary but typically range from 8 to 16 weeks for standard orders from established manufacturers, depending on production schedules and order volumes. Expedited orders may be possible but often incur additional costs.

4. How do different pharmacopoeial standards (USP, Ph. Eur., JP) compare for prednisolone tebutate API? While the core specifications for purity, assay, and identification are largely harmonized, minor differences may exist in impurity limits or specific analytical test methods between the USP, European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). Manufacturers typically aim to meet the most stringent of these standards to ensure broad market access.

5. What are the implications of a supplier having USFDA or EDQM approval for prednisolone tebutate API? USFDA (U.S. Food and Drug Administration) and EDQM (European Directorate for the Quality of Medicines & HealthCare) approvals signify that a manufacturer's facility and processes have been audited and deemed compliant with stringent cGMP standards for the production of APIs. This is critical for drug product manufacturers seeking to gain marketing authorization in the U.S. and European Union, respectively, as it substantiates the quality and reliability of the API source.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4: Good Manufacturing Practice. Retrieved from https://ec.europa.eu/health/documents/eudralex/volume-4_en [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1999). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from https://www.ich.org/page/quality-guidelines [4] Divi's Laboratories. (n.d.). Product Portfolio. Retrieved from the official Divi's Laboratories website. [5] Laurus Labs. (n.d.). APIs. Retrieved from the official Laurus Labs website. [6] Zydus Lifesciences. (n.d.). API Manufacturing. Retrieved from the official Zydus Lifesciences website. [7] Hengrui Medicine. (n.d.). Products. Retrieved from the official Jiangsu Hengrui Medicine website. [8] Sichuan Kelun Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from the official Sichuan Kelun Pharmaceutical website. [9] Lianyungang HEC Pharm. Co., Ltd. (n.d.). Products. Retrieved from the official Lianyungang HEC Pharm. website.